Cargando…

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

BACKGROUND: The AcSé-crizotinib program provides extensive screening of crizotinib-targeted genomic alteration in several malignancies. We here report the results in patients with esogastric MET-amplified adenocarcinomas. OBJECTIVE: The objective of the study was to evaluate the efficacy and tolerab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aparicio, Thomas, Cozic, Nathalie, de la Fouchardière, Christelle, Meriaux, Emeline, Plaza, Jérome, Mineur, Laurent, Guimbaud, Rosine, Samalin, Emmanuelle, Mary, Florence, Lecomte, Thierry, Gomez-Roca, Carlos, Haineaux, Paul-Arthur, Gratet, Alain, Selves, Jannick, Menu, Yves, Colignon, Nikias, Johnson, Laetitia, Legrand, Frédéric, Vassal, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105218/ https://www.ncbi.nlm.nih.gov/pubmed/33847874 http://dx.doi.org/10.1007/s11523-021-00811-8

Ejemplares similares

Crizotinib: A comprehensive review
por: Sahu, Arvind, et al.
Publicado: (2013)

Crizotinib: Pneumonitis: case report
Publicado: (2021)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Crizotinib targets in glioblastoma stem cells
por: Junca, Audelaure, et al.
Publicado: (2017)

Crizotinib-induced Rectal Perforation with Abscess
por: Yanagisawa, Asako, et al.
Publicado: (2017)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
por: Jalil, Ala' A Abdel, et al.
Publicado: (2014)

Crizotinib-Induced Abnormal Signal Processing in the Retina
por: Ishii, Toshiyuki, et al.
Publicado: (2015)

Complex renal cysts associated with crizotinib treatment
por: Schnell, Patrick, et al.
Publicado: (2015)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
por: Kwon, Jennifer, et al.
Publicado: (2012)

Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy
por: Huber, Kilian V. M., et al.
Publicado: (2014)

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

Renal Injury during Long-Term Crizotinib Therapy
por: Yasuma, Taro, et al.
Publicado: (2018)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
por: Hashimoto, Takahiko, et al.
Publicado: (2022)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
por: Rochigneux, Philippe, et al.
Publicado: (2018)

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment
por: Charville, Gregory W., et al.
Publicado: (2018)

Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
por: Cameron, Laird B, et al.
Publicado: (2017)

Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma
por: Verma, Priyanka, et al.
Publicado: (2017)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Renal Abscess Caused by Crizotinib: A Rare Case Report
por: Wan, Zhaojun, et al.
Publicado: (2022)

Isotopic Radiolabeling of Crizotinib with Fluorine-18 for In Vivo Pet Imaging
por: Sardana, Malvika, et al.
Publicado: (2022)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts, Patrick J
Publicado: (2013)

Role of Crizotinib in previously treated non-small-cell lung cancer
por: Gupta, Sunil Kumar
Publicado: (2014)

Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016)

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event
por: Adhikari, Narayan, et al.
Publicado: (2016)

Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib
por: Khalil, Sumaira, et al.
Publicado: (2020)

Crizotinib-Induced Severe Photosensitive Dermatitis in a Carcinoma Lung Patient
por: Afra, T. P., et al.
Publicado: (2020)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
por: Khan, Shaheer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ub4lsh131b3f0snabet5ialihe